Pieris Pharmaceuticals (NASDAQ: PIRS)
Some price data may be temporarily unavailable.
Pieris Pharmaceuticals Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Pieris Pharmaceuticals Company Info
Pieris Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of Anticalin-based drugs. Its pipeline includes immuno-oncology, respiratory, and anemia and other disease areas. The company was founded by Claus Schalper and Arne Skerra in 2001 and is headquartered in Boston, MA.
News & Analysis
This Pharmaceutical Stock Could Be Your Lottery Ticket
Pieris Pharmaceuticals has several drugs in clinical trials, but it only takes one to make this stock a hit.
This Pharmaceutical Stock Could Bank Billions Soon
Pieris Pharmaceuticals has several collaborations in place with big pharma.
2 Penny Stocks That Could Soar Soon
These two tiny drugmakers might be hidden gems.
Which Biotech Stock Will Shock the Market in 2022?
Over the last few years, three tiny biotechs emerged out of nowhere to give amazing returns to early investors. Which biotech might pull off a similar feat in 2022?
This Risky Micro-Cap Could Pay Off Big
Pieris Pharmaceuticals is introducing a whole new class of drugs to the marketplace.
3 Top Biotech Stocks to Buy in February
Want to cash in on the life sciences boom? Here are three stocks to check out.
Here's Why Pieris Pharmaceuticals Inc. Is Tanking
Shares drop after the company announces the pricing details of a common stock offering.
Why Pieris Pharmaceuticals Inc. Is Soaring Today
The signing of a lucrative collaboration deal causes the share price to jump.
Valuation
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.